title: Pharmacokinetic and pharmacodynamic properties of biapenem, a carbapenem antibiotic, in rat experimental model of severe acute pancreatitis.
abstract: OBJECTIVE
  It is known that prophylaxis with imipenem reduces the risk of infection accompanying severe acute pancreatitis. In this study,we modified a rat experimental model of severe acute pancreatitis for antibiotic evaluation, and the effect of biapenem was compared with that of imipenem to determine the usefulness of biapenem.
  
  
  METHODS
  Severe acute pancreatitis was induced by 5% sodium taurocholate. Antibiotics were subcutaneously administered at 3 and 6 hours and evaluated at 12 hours after the pancreatitis induction. For pharmacokinetic evaluation, antibiotics were subcutaneously administered at 3 hours after the pancreatitis induction.
  
  
  RESULTS
  From 3 hours after the induction, bacteria were detected from the pancreas. The total bacterial count increased in a time-dependent manner for 12 hours. Biapenem administration reduced the total bacterial count in the pancreas, as observed in imipenem administration. The plasma concentration of biapenem was almost equivalent to that of imipenem; however, the pancreatic penetration of biapenem was approximately twice that of imipenem in this model.
  
  
  CONCLUSIONS
  Biapenem was suggested to be effective in prophylactic treatment of infectious complications as much as imipenem because of its superior penetration to the pancreas in severe acute pancreatitis.
authors: Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan. yuko_muto@meiji.co.jp
authors: Yuko
authors: Y
authors: Muto
authors: Yukio
authors: Y
authors: Mikami
authors: Shiro
authors: S
authors: Sakakibara
authors: Atsuyuki
authors: A
authors: Shimizu
authors: Masashi
authors: M
authors: Niida
authors: Hiroshi
authors: H
authors: Kataoka
authors: Fumi
authors: F
authors: Ito
authors: Katsuyoshi
authors: K
authors: Suzuki
authors: Koji
authors: K
authors: Kijima
authors: Kazunori
authors: K
authors: Maebashi
authors: Toshihiko
authors: T
authors: Takata
authors: Muneo
authors: M
authors: Hikida
authors: Kazunori
authors: K
authors: Takeda
authors: Michiaki
authors: M
authors: Unno
mesh_terms: D000208:Acute Disease; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001201:Ascites / Q000382:microbiology; D001424:Bacterial Infections / Q000378:metabolism / Q000382:microbiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015378:Imipenem / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007279:Injections, Subcutaneous; D007422:Intestines / Q000382:microbiology; D008198:Lymph Nodes / Q000382:microbiology; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000382:microbiology; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D013656:Taurocholic Acid; D013845:Thienamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D013656:Taurocholic Acid; D015378:Imipenem; C065257:biapenem